Anavex Life Sciences Corp.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVXL research report →
Companywww.anavex.com
Anavex Life Sciences Corp. , a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex.
- CEO
- Christopher U. Missling
- IPO
- 2006
- Employees
- 42
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $254.85M
- P/E
- -6.13
- P/S
- 0.00
- P/B
- 1.93
- EV/EBITDA
- -3.08
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -38.76%
- ROIC
- -35.22%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-46,377,000 · -7.85%
- EPS
- $-0.54 · -3.85%
- Op Income
- $-51,408,000
- FCF YoY
- -26.72%
Performance & Tape
- 52W High
- $13.99
- 52W Low
- $2.61
- 50D MA
- $3.45
- 200D MA
- $5.79
- Beta
- 1.25
- Avg Volume
- 1.37M
Get TickerSpark's AI analysis on AVXL
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 4, 26 | Kellmeyer Terrie | other | 46,668 |
| May 4, 26 | Kellmeyer Terrie | other | 7,500 |
| May 4, 26 | Kellmeyer Terrie | other | 50,000 |
| Feb 23, 26 | Paeger Axel | other | 0 |
| Jan 6, 26 | MISSLING CHRISTOPHER U | other | 125,000 |
| Jan 6, 26 | Boenisch Sandra | other | 12,500 |
| Oct 2, 25 | Boenisch Sandra | other | 12,500 |
| Oct 2, 25 | MISSLING CHRISTOPHER U | other | 125,000 |
| Sep 11, 25 | MISSLING CHRISTOPHER U | other | 187,500 |
| Sep 11, 25 | MISSLING CHRISTOPHER U | other | 145,048 |
Our AVXL Coverage
We haven't published any research on AVXL yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AVXL Report →